Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia

CONCLUSIONS: Real-life, long-term evinacumab adjunctive to lipid-lowering therapy including lipoprotein apheresis led to sustained low-density lipoprotein cholesterol lowering and improved cardiovascular event-free survival of patients with HoFH.PMID:38695169 | DOI:10.1161/ATVBAHA.123.320609

Source: Arteriosclerosis, Thrombosis and Vascular Biology - May 2, 2024 Category: Cardiology Authors: Sophie B éliard Samir Saheb St éphanie Litzler-Renault Alexandre Vimont Ren é Valero Éric Bruckert Michel Farnier Antonio Gallo Source Type: research